Temozolomide resistance in glioblastoma multiforme
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair path...
Gespeichert in:
| Veröffentlicht in: | Genes & diseases 2016-09, Vol.3 (3), p.198-210 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 210 |
|---|---|
| container_issue | 3 |
| container_start_page | 198 |
| container_title | Genes & diseases |
| container_volume | 3 |
| creator | Lee, Sang Y. |
| description | Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs. |
| doi_str_mv | 10.1016/j.gendis.2016.04.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6150109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2352304216300162</els_id><sourcerecordid>2113269468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-2d6ef16d1793152f8596a895b76198a3c1244b9e78d04376ae8e2fbdf98cd4693</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMottT-A5EevXTN12aTiyDFLyh4qeeQTWZryu6mJtuC_nq3tGq9eJoZZuZ9Zx6ELgnOCCbiZpUtoXU-ZbSvMswzjIsTNKQsp1OGOT09ygdonNIKY0wYwzlX52jAMM2llGqI6AKa8Bnq0HgHkwjJp860Fia-nSxrH8rapC40ZtJs6s5XITZwgc4qUycYH-IIvT7cL2ZP0_nL4_Psbj61ueTdlDoBFRGOFIqRnFYyV8JIlZeFIEoaZgnlvFRQSIc5K4QBCbQqXaWkdVwoNkK3e931pmzAWWi7aGq9jr4x8UMH4_XfTuvf9DJstSA5JngncH0QiOF9A6nTjU8W6tq0EDZJU0IYFYoL2Y_y_aiNIaUI1Y8NwXpHXK_0nrjeEdeY6554v3Z1fOLP0jff3x-gB7X1EHWyHnq-zkewnXbB_-_wBdYJlE8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113269468</pqid></control><display><type>article</type><title>Temozolomide resistance in glioblastoma multiforme</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lee, Sang Y.</creator><creatorcontrib>Lee, Sang Y.</creatorcontrib><description>Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.</description><identifier>ISSN: 2352-3042</identifier><identifier>ISSN: 2352-4820</identifier><identifier>EISSN: 2352-3042</identifier><identifier>DOI: 10.1016/j.gendis.2016.04.007</identifier><identifier>PMID: 30258889</identifier><language>eng</language><publisher>China: Elsevier B.V</publisher><subject>Adaptive ; Glioblastoma ; Intrinsic ; Resistance ; Temodar ; Temozolomide</subject><ispartof>Genes & diseases, 2016-09, Vol.3 (3), p.198-210</ispartof><rights>2016 Chongqing Medical University</rights><rights>Copyright © 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. 2016 Chongqing Medical University</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-2d6ef16d1793152f8596a895b76198a3c1244b9e78d04376ae8e2fbdf98cd4693</citedby><cites>FETCH-LOGICAL-c584t-2d6ef16d1793152f8596a895b76198a3c1244b9e78d04376ae8e2fbdf98cd4693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150109/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150109/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30258889$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sang Y.</creatorcontrib><title>Temozolomide resistance in glioblastoma multiforme</title><title>Genes & diseases</title><addtitle>Genes Dis</addtitle><description>Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.</description><subject>Adaptive</subject><subject>Glioblastoma</subject><subject>Intrinsic</subject><subject>Resistance</subject><subject>Temodar</subject><subject>Temozolomide</subject><issn>2352-3042</issn><issn>2352-4820</issn><issn>2352-3042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMottT-A5EevXTN12aTiyDFLyh4qeeQTWZryu6mJtuC_nq3tGq9eJoZZuZ9Zx6ELgnOCCbiZpUtoXU-ZbSvMswzjIsTNKQsp1OGOT09ygdonNIKY0wYwzlX52jAMM2llGqI6AKa8Bnq0HgHkwjJp860Fia-nSxrH8rapC40ZtJs6s5XITZwgc4qUycYH-IIvT7cL2ZP0_nL4_Psbj61ueTdlDoBFRGOFIqRnFYyV8JIlZeFIEoaZgnlvFRQSIc5K4QBCbQqXaWkdVwoNkK3e931pmzAWWi7aGq9jr4x8UMH4_XfTuvf9DJstSA5JngncH0QiOF9A6nTjU8W6tq0EDZJU0IYFYoL2Y_y_aiNIaUI1Y8NwXpHXK_0nrjeEdeY6554v3Z1fOLP0jff3x-gB7X1EHWyHnq-zkewnXbB_-_wBdYJlE8</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Lee, Sang Y.</creator><general>Elsevier B.V</general><general>Chongqing Medical University</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160901</creationdate><title>Temozolomide resistance in glioblastoma multiforme</title><author>Lee, Sang Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-2d6ef16d1793152f8596a895b76198a3c1244b9e78d04376ae8e2fbdf98cd4693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adaptive</topic><topic>Glioblastoma</topic><topic>Intrinsic</topic><topic>Resistance</topic><topic>Temodar</topic><topic>Temozolomide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sang Y.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genes & diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sang Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Temozolomide resistance in glioblastoma multiforme</atitle><jtitle>Genes & diseases</jtitle><addtitle>Genes Dis</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>3</volume><issue>3</issue><spage>198</spage><epage>210</epage><pages>198-210</pages><issn>2352-3042</issn><issn>2352-4820</issn><eissn>2352-3042</eissn><abstract>Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.</abstract><cop>China</cop><pub>Elsevier B.V</pub><pmid>30258889</pmid><doi>10.1016/j.gendis.2016.04.007</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2352-3042 |
| ispartof | Genes & diseases, 2016-09, Vol.3 (3), p.198-210 |
| issn | 2352-3042 2352-4820 2352-3042 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6150109 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adaptive Glioblastoma Intrinsic Resistance Temodar Temozolomide |
| title | Temozolomide resistance in glioblastoma multiforme |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A45%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Temozolomide%20resistance%20in%20glioblastoma%20multiforme&rft.jtitle=Genes%20&%20diseases&rft.au=Lee,%20Sang%20Y.&rft.date=2016-09-01&rft.volume=3&rft.issue=3&rft.spage=198&rft.epage=210&rft.pages=198-210&rft.issn=2352-3042&rft.eissn=2352-3042&rft_id=info:doi/10.1016/j.gendis.2016.04.007&rft_dat=%3Cproquest_pubme%3E2113269468%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2113269468&rft_id=info:pmid/30258889&rft_els_id=S2352304216300162&rfr_iscdi=true |